Clinical trial · Observational
Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer
Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer Patients Who Receive Neoadjuvant Chemotherapy; Observational Pilot Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aimed to evaluate the feasibility of dual sentinel node staining method using mixture of indocyanine green(ICG) and radioisotope (RI) in breast cancer patients who receive neoadjuvant chemotherapy. Over the past few years, several studies have found using methylene blue, isosulfan blue, indocyanine green or radioisotope alone by detection method had several disadvantages. In this study we expects using mixture of indocyanine green (ICG) with radioisotope (RI) has potential to improve sentinel lymph node (SLN) mapping in breast cancer patients who receive neoadjuvant chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| sentinel lymph node biopsy(SLNB) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Identification rate of sentinal lymph node biopsy
- timeFrame
- during operation
- description
- It was defined as the ability to identify a sentinel lymph node successfully.
Secondary outcomes (1)
- measure
- duration of sentinel lymph node biopsy
- timeFrame
- during operation
- description
- It was defined as the time from the skin incision to complet removal of the first sentinel lymph node.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * breast cancer patients who receive neoadjuvant chemotherapy * cN1-cN2 or cT2 on tumor lymphnode metastasis classification(TNM) * ECOG Performance status 0 or 1 * consented patients with more than 20 years, less than 70 years Exclusion Criteria: * history of breast cancer * early stage breast cancer * history of excisional or incisional biopsy or axillary dissection * inflammatory breast carcinoma * cN3 on tumor lymphnode metastasis classification(TNM) * history of hormone therapy or targeted therapy * stage 4 breast cancer * pregnancy
References
Publications (0)
Data not yet available